More on IRD
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.77 |
|
|||
| Open | $4.77 | ||||
| 52 Wk High | $0.02 | ||||
| 52 Wk Low | $0.02 | ||||
| Day High | $5.10 | ||||
| Day Low | $4.68 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,517,951 | ||||
- Opus Genetics to Present at Upcoming Investor Conferences in March 2026
- Opus Genetics (IRD) PT Raised to $10 at Jones Trading
- Opus Genetics reports initial data from gene therapy trial
- Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
- FDA accepts Opus Genetics presbyopia drug application
- Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
- Form 8-K Opus Genetics, Inc. For: Feb 13
- Form 4 Opus Genetics, Inc. For: Feb 12 Filed by: Jayagopal Ashwath
- Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: PERCEPTIVE ADVISORS LLC
- Form SCHEDULE 13G Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
Entities mentioned with IRD
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- S3 | View Related Stories »
- 13G | View Related Stories »
- Show More...
